Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
3(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
2
33%
Ph phase_2
3
50%

Phase Distribution

0

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(3)
Completed(3)

Detailed Status

Completed3
Recruiting3

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (60.0%)
Phase 32 (40.0%)

Trials by Status

completed350%
recruiting350%

Recent Activity

3 active trials
Showing 5 of 6
recruitingphase_2

Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT04881682
recruitingphase_2

Intravenous Immunoglobulin Replacement Therapy for Persistent COVID-19 in Patients With B-cell Impairment

NCT06159283
recruitingphase_2

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension

NCT05678621
completedphase_3

Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185)

NCT00000590
completed

Immunoglobulin Dosage and Administration Form in CIDP and MMN

NCT02111590
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04881682Phase 2

Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Recruiting
NCT06159283Phase 2

Intravenous Immunoglobulin Replacement Therapy for Persistent COVID-19 in Patients With B-cell Impairment

Recruiting
NCT05678621Phase 2

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension

Recruiting
NCT00000590Phase 3

Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185)

Completed
NCT02111590

Immunoglobulin Dosage and Administration Form in CIDP and MMN

Completed
NCT00000584Phase 3

Transfusion-Transmitted Cytomegalovirus Prevention in Neonates

Completed

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6